171 related articles for article (PubMed ID: 35800989)
21. Identification of three molecular subtypes based on immune infiltration in ovarian cancer and its prognostic value.
Liu J; Tan Z; He J; Jin T; Han Y; Hu L; Song J; Huang S
Biosci Rep; 2020 Oct; 40(10):. PubMed ID: 33043974
[TBL] [Abstract][Full Text] [Related]
22. Analysis in epithelial ovarian cancer identifies KANSL1 as a biomarker and target gene for immune response and HDAC inhibition.
Fejzo MS; Chen HW; Anderson L; McDermott MS; Karlan B; Konecny GE; Slamon DJ
Gynecol Oncol; 2021 Feb; 160(2):539-546. PubMed ID: 33229045
[TBL] [Abstract][Full Text] [Related]
23. Integrative prognostic subtype discovery in high-grade serous ovarian cancer.
Xie H; Xu H; Hou Y; Cai Y; Rong Z; Song W; Wang W; Li K
J Cell Biochem; 2019 Nov; 120(11):18659-18666. PubMed ID: 31347734
[TBL] [Abstract][Full Text] [Related]
24. Metabolic Signature-Based Subtypes May Pave Novel Ways for Low-Grade Glioma Prognosis and Therapy.
Li G; Wu Z; Gu J; Zhu Y; Zhang T; Wang F; Huang K; Gu C; Xu K; Zhan R; Shen J
Front Cell Dev Biol; 2021; 9():755776. PubMed ID: 34888308
[TBL] [Abstract][Full Text] [Related]
25. Identification of metabolism-associated molecular subtype in ovarian cancer.
Liu X; Wu A; Wang X; Liu Y; Xu Y; Liu G; Liu L
J Cell Mol Med; 2021 Oct; 25(20):9617-9626. PubMed ID: 34523782
[TBL] [Abstract][Full Text] [Related]
26. FOXM1 expression is significantly associated with chemotherapy resistance and adverse prognosis in non-serous epithelial ovarian cancer patients.
Tassi RA; Todeschini P; Siegel ER; Calza S; Cappella P; Ardighieri L; Cadei M; Bugatti M; Romani C; Bandiera E; Zanotti L; Tassone L; Guarino D; Santonocito C; Capoluongo ED; Beltrame L; Erba E; Marchini S; D'Incalci M; Donzelli C; Santin AD; Pecorelli S; Sartori E; Bignotti E; Odicino F; Ravaggi A
J Exp Clin Cancer Res; 2017 May; 36(1):63. PubMed ID: 28482906
[TBL] [Abstract][Full Text] [Related]
27. Development of a multi-gene-based immune prognostic signature in ovarian Cancer.
Cao T; Shen H
J Ovarian Res; 2021 Jan; 14(1):20. PubMed ID: 33509250
[TBL] [Abstract][Full Text] [Related]
28. Novel gene signatures for prognosis prediction in ovarian cancer.
Bao M; Zhang L; Hu Y
J Cell Mol Med; 2020 Sep; 24(17):9972-9984. PubMed ID: 32666642
[TBL] [Abstract][Full Text] [Related]
29. A new thinking: extended application of genomic selection to screen multiomics data for development of novel hypoxia-immune biomarkers and target therapy of clear cell renal cell carcinoma.
Gui CP; Wei JH; Chen YH; Fu LM; Tang YM; Cao JZ; Chen W; Luo JH
Brief Bioinform; 2021 Nov; 22(6):. PubMed ID: 34237133
[TBL] [Abstract][Full Text] [Related]
30. Development and validation of an immune gene-set based Prognostic signature in ovarian cancer.
Shen S; Wang G; Zhang R; Zhao Y; Yu H; Wei Y; Chen F
EBioMedicine; 2019 Feb; 40():318-326. PubMed ID: 30594555
[TBL] [Abstract][Full Text] [Related]
31. Multifactor assessment of ovarian cancer reveals immunologically interpretable molecular subtypes with distinct prognoses.
Guo Y; Li S; Li C; Wang L; Ning W
Front Immunol; 2023; 14():1326018. PubMed ID: 38143770
[TBL] [Abstract][Full Text] [Related]
32. Gene expression classification of colon cancer into molecular subtypes: characterization, validation, and prognostic value.
Marisa L; de Reyniès A; Duval A; Selves J; Gaub MP; Vescovo L; Etienne-Grimaldi MC; Schiappa R; Guenot D; Ayadi M; Kirzin S; Chazal M; Fléjou JF; Benchimol D; Berger A; Lagarde A; Pencreach E; Piard F; Elias D; Parc Y; Olschwang S; Milano G; Laurent-Puig P; Boige V
PLoS Med; 2013; 10(5):e1001453. PubMed ID: 23700391
[TBL] [Abstract][Full Text] [Related]
33. Downregulated Long Noncoding RNA DGCR5 Acts as a New Promising Biomarker for the Diagnosis and Prognosis of Ovarian Cancer.
Chen H; Tian X; Luan Y; Lu H
Technol Cancer Res Treat; 2019; 18():1533033819896809. PubMed ID: 31868103
[TBL] [Abstract][Full Text] [Related]
34. Construction of a ceRNA network of hub genes affecting immune infiltration in ovarian cancer identified by WGCNA.
Su R; Jin C; Zhou L; Cao Y; Kuang M; Li L; Xiang J
BMC Cancer; 2021 Aug; 21(1):970. PubMed ID: 34461858
[TBL] [Abstract][Full Text] [Related]
35. Single-cell analysis revealed that IL4I1 promoted ovarian cancer progression.
Zhao H; Teng Y; Hao W; Li J; Li Z; Chen Q; Yin C; Yue W
J Transl Med; 2021 Oct; 19(1):454. PubMed ID: 34717685
[TBL] [Abstract][Full Text] [Related]
36. Decoding transcriptomic intra-tumour heterogeneity to guide personalised medicine in ovarian cancer.
Tan TZ; Heong V; Ye J; Lim D; Low J; Choolani M; Scott C; Tan DSP; Huang RY
J Pathol; 2019 Mar; 247(3):305-319. PubMed ID: 30374975
[TBL] [Abstract][Full Text] [Related]
37. Identification of novel subtypes based on ssGSEA in immune-related prognostic signature for tongue squamous cell carcinoma.
Jin Y; Wang Z; He D; Zhu Y; Chen X; Cao K
Cancer Med; 2021 Dec; 10(23):8693-8707. PubMed ID: 34668665
[TBL] [Abstract][Full Text] [Related]
38. Computed Tomography Imaging-Based Radiogenomics Analysis Reveals Hypoxia Patterns and Immunological Characteristics in Ovarian Cancer.
Feng S; Xia T; Ge Y; Zhang K; Ji X; Luo S; Shen Y
Front Immunol; 2022; 13():868067. PubMed ID: 35418998
[TBL] [Abstract][Full Text] [Related]
39. A DNA repair pathway-focused score for prediction of outcomes in ovarian cancer treated with platinum-based chemotherapy.
Kang J; D'Andrea AD; Kozono D
J Natl Cancer Inst; 2012 May; 104(9):670-81. PubMed ID: 22505474
[TBL] [Abstract][Full Text] [Related]
40. Ovarian cancer classification and prognosis assessment model based on prognostic target genes in key microRNA-target gene networks.
Chen X; Li Y; He J
J Gene Med; 2024 Jan; 26(1):e3575. PubMed ID: 37548130
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
